Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Tecfidera(®): an approach for repurposing.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Study hints of rituximab MS benefit
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Colestipol May Quickly Eliminate Teriflunomide
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Differential roles of microglia and monocytes in the inflamed central nervous system.
Good Early Results for HERV Suppressor in MS
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Ofatumumab
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Reactive astrocytes as therapeutic targets for CNS disorders.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Pharmacokinetic properties and metabolism of idebenone.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Roche's MabThera approved for two vasculitis indications in UK

Pages